Shilpa Medicare Limited (NSE:SHILPAMED)
945.70
+11.85 (1.27%)
Nov 11, 2026, 1:00 PM IST
Shilpa Medicare Revenue
Shilpa Medicare had revenue of 5.29B INR in the quarter ending September 30, 2026, with 43.01% growth. This brings the company's total for the last twelve months to 18.44B, up 37.27% year-over-year. In the fiscal year ending March 31, 2026, Shilpa Medicare had annual revenue of 15.40B with 19.60% growth.
Revenue (ttm)
18.44B
Revenue Growth
+37.27%
P/S Ratio
9.91
Revenue / Employee
14.86M
Employees
1,241
Market Cap
185.08B
Revenue by Geography
- India 5.46B 35.5%
- Europe 4.43B 28.8%
- Rest of The World 3.91B 25.4%
- USA 1.59B 10.3%
Fiscal year ended Mar 31, 2026 See the full Shilpa Medicare breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 15.40B | 2.52B | 19.60% |
| Mar 31, 2025 | 12.88B | 1.35B | 11.69% |
| Mar 31, 2024 | 11.53B | 1.01B | 9.64% |
| Mar 31, 2023 | 10.52B | -952.56M | -8.31% |
| Mar 31, 2022 | 11.47B | 2.45B | 27.21% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Piramal Pharma | 97.79B |
| Alembic Pharmaceuticals | 84.77B |
| Strides Pharma Science | 52.13B |
| Akums Drugs and Pharmaceuticals | 48.29B |
| Wockhardt | 38.40B |
| NATCO Pharma | 34.85B |
| Eris Lifesciences | 33.12B |
| Alivus Life Sciences | 26.84B |
Shilpa Medicare News
- 4 months ago - Shilpa Medicare partners with Orion for nivolumab biosimilar development in Europe - Business Upturn
- 4 months ago - Shilpa Medicare commissions state-of-the-art ADC manufacturing facility - Business Upturn
- 5 months ago - Shilpa Medicare and Gate2brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy - Business Upturn
- 5 months ago - Shilpa Medicare subsidiary invests €7 million for 30.4% stake in Gate2Brain - Business Upturn
- 5 months ago - Shilpa Medicare Q4 Results: Net profit jumps over 7x to Rs 108 crore, revenue up 32% - Business Upturn
- 7 months ago - Pharma sector stocks today, April 6: Shilpa Medicare down 3.07%, Ipca Labs decline 2.42%, Sun Pharma falls 1.42% - Business Upturn
- 7 months ago - Pharma sector stocks today, March 24: Shilpa Medicare jumps 3.28%, Glenmark Pharma up 1.36%, Laurus Labs gain 1.65% - Business Upturn
- 8 months ago - Pharma sector stocks today, March 6: Shilpa Medicare surge 3.08%, Wockhardt jumps 2.12%, Natco Pharma up 1.84%, - Business Upturn